REPLY
31.3.2022 09:32:08 CEST | Business Wire | Press release
Storm Reply, specialised in the design and implementation of innovative cloud-based solutions and services and AWS Premier Consulting Partner, supported the leading mechanical engineering company Schenck Process in developing the serverless, modular IoT platform CONiQ Cloud .
CONiQ Cloud is the IoT backbone to make machines and processes smarter. It provides digital process solutions to save production time and deliver critical insights in near real-time, creating a broader window of opportunity for data-driven responses.
Schenck Process is evolving from a traditional machine builder to an Industry 4.0 company, going beyond its traditional business field and positioning itself as a digital service provider and pioneer for its customers . Schenck Process enables data-driven optimisation of processes through the use of IoT and cloud computing. With this purpose in mind, Storm Reply selected the appropriate AWS building blocks and developed an individual Industrial IoT (IIoT) solution that meets the customer-specific requirements.
Standard core IoT functions available include: organisational and machine management, analytics integration, machine and process data visualisation, email notification, and secure data connection and streaming to CONiQ Monitor - Schenck Process' condition-based monitoring sensor system.
Both the serverless architecture and the high degree of automation offer economic advantages and the modular structure, on the other hand, enables the flexible adaptation to specific customer needs, paving the way for further innovations. These include real-time insights from production processes , the use of machine learning for early warning of deviations from standard processes during production; focusing on predictive quality assurance and maintenance scenarios .
"We intend to reach more customers and integrate additional processes with existing clients, and that's where the modular structure and flexibility of integration pays off," says Benedikt Trumpff, Head of iQ Systems and Services at Schenck Process . "What we ultimately offer our customers with the CONiQ Cloud is additional production time – that is more valuable than anything else. With the new functionalities we are implementing, we can also develop algorithms that deliver Process Insights-as-a-Service, which translate process data into actionable insights that would otherwise be inaccessible to customers."
The CONiQ Cloud enables the processing of data from various sources as it can be connected to any customer system and easily scaled with further functionalities. This creates the conditions for building intelligent machines and establishing smarter processes.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] is specialised in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly focused companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media, and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
Storm Reply
Storm Reply is the Reply Group company specializing in design and implementation of cloud-based solutions and services. Having a consolidated experience in Cloud IaaS, PaaS and SaaS architectures, Storm Reply provides an end to end set of services for Cloud Adoption, Development of new applications and management full services of their cloud environment. Having deep competencies and experiences on management of complex cloud projects, Storm Reply helps customers to implement their Strategy Cloud Approach. In particular, Storm Reply offers services on Cloud Strategy and Migration, Cloud Native Applications development and Cloud Service Management. www.storm.reply.com
Schenck Process
Schenck Process is a leading global provider of sustainable products, integrated solutions and services for bulk solids. Headquartered in Darmstadt, Germany, the Group is represented in over 20 countries on five continents and focuses primarily on the market segments "Food", "Mining", "Chemical and Performance Materials" and "Infrastructure and Energy". The product range includes solutions for industrial weighing, feeding, conveying, screening, mixing and extruding as well as digital applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom